a new method to targeting cancer cells is represented by the term osimertinib covalent inhibitory agent, which has gained significant attention in the drug industry.The term osimertinib covalent inhibitory agent denotes a type of covalent inhibitory agent, which focuses on targeted tyrosine kinases that are responsible for the growth and division of cancer cells.For patients suffering from lung carcinoma, particularly those with EGFR (EGFR) mutations, this inhibitor has the capacity to provide a more efficient and precision therapeutic approach.A growing requirement for more efficient targeted therapies is observed due to…
